Thermo Fisher Scientific buys Brammer Bio

Thermo Fisher Scientific Inc. is to acquire Brammer Bio, a viral vector contract development and manufacturing organization for gene and cell therapies, facilitating the delivery of breakthrough medicines to patients by releasing the potential of gene therapies and gene-modified cell therapies.
Co-founders of Brammer Bio, Mark Bamforth, president and CEO, and Dr. Richard Snyder, chief scientific officer, said: “We are proud to be pioneers in process development and manufacturing of viral vectors. Brammer Bio has executed more than 100 projects to supply first-in-human gene therapy clinical trials and establish commercial-ready processes, and we’re excited to join Thermo Fisher to take our business to the next level. Our teams share a commitment to helping our customers succeed in delivering cutting-edge therapies to patients in need.”
Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific, said: “Brammer Bio will be an exciting addition to our pharma services business and will further strengthen Thermo Fisher’s leadership in serving pharma and biotech customers. Gene therapy is an area of increasing focus for our customers and is fast-evolving given its potential to treat a range of genetic disorders. The combination of Brammer Bio’s viral vector capabilities with our GMP production expertise and proprietary bioprocessing and cell culture technologies uniquely positions us to partner with our customers to drive the evolution of this incredibly fast-growing market. The transaction is perfectly aligned with our Mission to enable our customers to make the world healthier, cleaner and safer.”
President of Thermo Fisher’s pharma services business, Michel Lagarde, said: “By leveraging our combined capabilities, along with our commercial scale and customer relationships, we will strengthen our position as a trusted partner to pharma and biotech. We look forward to welcoming the Brammer Bio team to our company and working together to make more life-saving treatments available to patients.”